Literature DB >> 112519

Extraction and identification of a human pancreatic-tumor-associated antigen.

D J Kuntz, S J Archer.   

Abstract

In attempting to develop an immunoassay to aid in the early diagnosis of cancer of the pancreas, a pancreatic-tumor-associated antigen (TAA) was identified and partially purified. The antigen has a molecular weight of approximately 380,000, does not cross-react with carcinoembryonic antigen (CEA), and is apparently either not present or not readily detectable in normal pancreatic tissue. The development of an immunoassay employing such an antigen to aid in the diagnosis of cancer of the pancreas at an early stage of development is discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 112519     DOI: 10.1159/000225365

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  4 in total

1.  A pancreatic oncofetal antigen: its partial purification and clinical application.

Authors:  T Homma; H Oguchi; S Kawa
Journal:  Gastroenterol Jpn       Date:  1981

2.  Monoclonal antibody defines CA 19-9 in pancreatic juices and sera.

Authors:  W H Schmiegel; C Kreiker; W Eberl; R Arndt; M Classen; H Greten; K Jessen; H Kalthoff; N Soehendra; H G Thiele
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

3.  Enzyme immunoassay of pancreatic oncofetal antigen (POA) as a marker of pancreatic cancer.

Authors:  K Nishida; M Sugiura; T Yoshikawa; M Kondo
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

4.  Reactivity of monoclonal anti-human pancreatic carcinoma antibodies AR2-20 and AR1-28 with tumors of nonpancreatic origin.

Authors:  J Chin; R Zuna; F Miller
Journal:  Am J Pathol       Date:  1987-01       Impact factor: 4.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.